Difficile clinical trials at University of California Health

• Optimal Treatment for Recurrent Clostridium Difficile

  open to eligible people ages 18 years and up

  The purpose of this study is to determine whether fidaxomicin and vancomycin followed by taper and pulse vancomycin treatment are superior to standard vancomycin treatment for the treatment of recurrent Clostridium difficile infection.

  at UCSD

Last updated: July 2, 2021